Cardiology in 2025: Year in Review

Cardiology has seen rapid evolution over the past year, between the constant advancement of GLP-1 receptor agonists and a series of rapid-fire approvals from the US Food and Drug Administration (FDA). Updated clinical guidelines on heart failure (HF) and hypertension from various research organizations reinforced existing treatment algorithms and addressed gaps in disease management. And a new clinical definition of obesity as a disease rather than a risk factor established a path forward for managing one of the most critical epidemics facing cardiology.